ストックスクリーナーアプリを入手
23.31
0.77%
-0.18
前日終値:
$23.49
開ける：
$24.165
24時間の取引高:
2.52M
Relative Volume:
1.38
時価総額：
$3.70B
収益：
$1.27M
当期純損益:
$-508.02M
株価収益率:
-8.0918
EPS:
-2.8807
ネットキャッシュフロー:
$-419.23M
1週間 パフォーマンス:
+10.89%
1か月 パフォーマンス:
+26.68%
6か月 パフォーマンス:
+39.00%
1年 パフォーマンス:
+65.44%
1日の値動き範囲:
$23.21
$24.65
1週間の範囲:
$20.92
$24.65
52週間の値動き範囲:
$12.58
$24.65
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
23.31 | 3.70B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics StockAnalyst focus and sector check after a quiet news week - AD HOC NEWS
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod - Citeline News & Insights
Sector Update: Healthcare Stocks Advance Premarket Thursday - Moomoo
Denali Therapeutics Files 8-K Report Detailing Company Information and Latest Press Release – June 2026 - Minichart
Denali Therapeutics to sell priority review voucher for $195m - Investing.com
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Denali to sell priority review voucher for $195M (DNLI:NASDAQ) - Seeking Alpha
Denali sells Rare Pediatric Disease Priority Review Voucher for $195M to fund neurodegenerative drug development. - Pluang
Denali Monetizes FDA Voucher to Advance CNS Pipeline - TipRanks
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million - The Manila Times
Denali Therapeutics to Sell FDA Priority Review Voucher for $195 Million - TradingView
Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M - Stock Titan
Denali’s rare disease voucher sale brings in $195 million - Stock Titan
Denali Therapeutics stock hits 52-week high at 23.78 USD By Investing.com - Investing.com Nigeria
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc (DNLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Denali Therapeutics Inc (DNLI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Denali Therapeutics Inc (DNLI) Institutional Confidence - TradingKey
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch By Investing.com - Investing.com Nigeria
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch - Investing.com
Denali Therapeutics Inc (DNLI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(DNLI) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Denali Therapeutics Halts Parkinson Drug Collaboration With Biogen - HarianBasis.co
Denali Therapeutics (DNLI) Rallies Over 3% as Stock Tests Key Resistance LevelsStock Analysis - newsline.com
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment - biocentury.com
Denali Therapeutics stock (US24823R1077): Alzheimer’s data and Roche deal keep Wall Street watchin - AD HOC NEWS
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Denali Therapeutics (DNLI) grants RSUs and stock options to director - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and options in new award - Stock Titan
Denali Therapeutics (DNLI) director receives RSU and stock option awards - Stock Titan
Director at Denali Therapeutics (NASDAQ: DNLI) receives RSUs and options - Stock Titan
Denali Therapeutics (DNLI) director receives new RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and stock options in new equity awards - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) details Baker RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay - Stock Titan
Responsive Playbooks and the DNLI Inflection - Stock Traders Daily
DNLI PE Ratio & Valuation, Is DNLI Overvalued - Intellectia AI
DNLI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Insider Monkey
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy? - simplywall.st
DNLI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline - Sahm
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):